Age-related Macular Degeneration Treatment Market Size, Share, Report By 2033

Prathamesh

9 months ago

The global age-related macular degeneration treatment market size is expected to increase USD 22.05 billion by 2033 from USD 11.28 billion in 2023 with a CAGR of 6.93% between 2024 and 2033.

Key Points

The North America age-related macular degeneration treatment market size reached USD 5.75 billion in 2023 and is expected to expand around USD 11.36 billion by 2033, at a CAGR of 7.04% from 2024 to 2033.
North America led the market with the largest revenue share of 51% in 2023.
Asia-Pacific is expected to experience the fastest rate of growth during the forecast period.
By product, the eylea segment has held a major revenue share of 52% in 2023.
By product, the Beovu segment is expected to grow with the highest CAGR during the forecast period.
By disease type, the wet AMD segment has contributed more than 98% of revenue share in 2023.
By disease type, the dry AMD segment is expected to be the fastest-growing segment during the forecast period.
By distribution channel, the hospital pharmacy segment has held a biggest revenue share of 52% in 2023.
By distribution channel, the specialty pharmacy segment is estimated to witness the fastest growth during the forecast period.

The Age-related Macular Degeneration (AMD) treatment market encompasses a range of therapies and interventions aimed at managing and potentially reversing the progression of AMD, a common eye condition among older adults. AMD affects the macula, a part of the retina responsible for central vision, leading to blurred or distorted vision and, in advanced stages, significant vision loss. As the global population ages, the prevalence of AMD is expected to rise, driving demand for effective treatments and therapies. This market overview explores the current landscape of AMD treatment, including growth factors, trends, regional insights, drivers, opportunities, and challenges.

Get a Sample: https://www.precedenceresearch.com/sample/4462

Growth Factors

The growth of the AMD treatment market is primarily driven by the increasing aging population worldwide. As individuals age, the risk of developing AMD significantly rises, leading to a larger patient pool requiring treatment. Advances in medical technology and diagnostics have also contributed to the growth of this market by enabling early detection and intervention, thereby improving outcomes for AMD patients. Additionally, rising healthcare expenditure and growing awareness about eye health among the elderly population are further boosting market growth.

Trends

Several key trends are shaping the AMD treatment market. Personalized medicine approaches, such as genetic testing to identify individuals at high risk for AMD, are gaining traction. This allows healthcare providers to tailor treatments based on genetic predispositions and disease progression patterns. Moreover, there is a notable shift towards minimally invasive treatment options, including intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents, which have revolutionized the management of AMD by reducing the need for invasive surgeries.

Region Insights

Regionally, North America and Europe dominate the AMD treatment market due to well-established healthcare infrastructure, higher healthcare expenditure, and early adoption of advanced treatment modalities. In these regions, government initiatives and supportive reimbursement policies also play a crucial role in market growth. Asia-Pacific is expected to witness significant growth in the coming years, driven by increasing healthcare spending, expanding geriatric population, and improving access to healthcare services in countries like China, India, and Japan.

Age-related Macular Degeneration Treatment Market Scope

Report Coverage	Details
Market Size in 2023	USD 11.28 Billion
Market Size in 2024	USD 12.06 Billion
Market Size by 2033	USD 22.05 Billion
Market Growth Rate	CAGR of 6.93% from 2024 to 2033
Largest Market	North America
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	Product, Disease Type, Distribution Channel, and Regions
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Age-related Macular Degeneration Treatment Market Dynamics

Drivers

Key drivers of the AMD treatment market include advancements in pharmaceuticals and biotechnology, particularly the development of novel therapeutic agents targeting specific pathways involved in AMD pathogenesis. The growing prevalence of risk factors such as smoking, obesity, and hypertension also contributes to the rising incidence of AMD, thereby driving demand for effective treatments. Furthermore, collaborations between research institutions, pharmaceutical companies, and healthcare providers are fostering innovation in AMD treatment strategies.

Opportunities

The AMD treatment market presents several opportunities for growth and innovation. One such opportunity lies in the development of combination therapies that target multiple pathways implicated in AMD progression, potentially enhancing treatment efficacy and patient outcomes. Additionally, expanding market penetration in emerging economies presents a lucrative opportunity for pharmaceutical companies and healthcare providers to address the unmet medical needs of AMD patients in these regions. Moreover, ongoing clinical trials and research initiatives aimed at exploring novel therapeutic targets offer promising avenues for future market expansion.

Challenges

Despite its growth prospects, the AMD treatment market faces several challenges. High treatment costs associated with novel therapies, such as anti-VEGF injections, pose a significant financial burden on healthcare systems and patients alike. Access to specialized healthcare services and diagnostic tools remains limited in some regions, particularly in low-income countries, hindering timely diagnosis and treatment initiation. Moreover, the variability in treatment response among AMD patients underscores the need for personalized medicine approaches and further research into predictive biomarkers.

Age-related Macular Degeneration Treatment Market Companies

F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
Amgen Inc.
Bayer AG
Biogen
Samsung Bioepis
Abbvie, Inc

Recent Developments

In October 2023, Genentech announced that the U.S. Food and Drug Administration (FDA) had approved Vabysmo for the treatment of Retinal Vein Occlusion (RVO), neovascular or wet age-related macular degeneration, and diabetic macular edema.
In August 2023, Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved EYLEA HD injection for treating patients suffering from wet age-related macular degeneration.
In August 2023, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) had approved IZERVAY injection for geographic atrophy (GA) and age-related macular degeneration (AMD) disease.
In February 2023, Apellis announced that the U.S. Food and Drug Administration (FDA) had approved SYFOVRE injection for the treatment of geographic atrophy (GA) and age-related macular degeneration (AMD) disease.

Segments Covered in the Report

By Product